In contrast, the large-size cohort studies on clinical characteristics of COVID-19 indicated that despite of 0.6–2.1% patients with liver disease comorbidity, 21.3–58.4% patients upon hospital admission presented abnormal liver biochemistry (e.g., ALT, AST) (28–30). This evidence concerns the gene GPT and COVID-19.